# US 2023/0111672 A1 · Compositions and methods for production of recombinant adeno-associated virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0111672 A1
- Document ID: US20230111672A1
- Status: Published application
- Kind: A1
- Application number: 17/911,306
- Filed: 2021-04-20
- Published: 2023-04-13
- Earliest claimed: 2020-04-27
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: David Vernon Schaffer; Hyuncheol Lee; Christopher Ryan Barnes
- Web page: https://patentgrep.com/patent/US20230111672A1

## CPC

- C12N 15/86: Viral vectors
- C12N 15/69: Increasing the copy number of the vector
- C12N 2710/00052: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14151: Methods of production or purification of viral material
- C12N 2750/14152: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides methods for producing recombinant adeno-associated virus (rAAV) virions. The present disclosure provides compositions for producing rAAV virions.

## Claims

### Claim 1

A method for producing recombinant adeno-associated virus (rAAV) virions, the method comprising:
culturing a eukaryotic cell in a culture medium, wherein the eukaryotic cell comprises one or more nucleic acids comprising:
a) nucleotide sequences encoding AAV rep and cap gene products; and
b) a nucleotide sequence encoding one or more heterologous gene products,
wherein the culture medium comprises a cell cycle blocking agent in a concentration of from about 1 mM to about 100 mM and
wherein said culturing results in production of the rAAV virions.

### Claim 2 (depends on 1)

The method of claim 1, wherein the culture medium comprises the cell cycle blocking agent in a concentration of from about 3 mM to about 10 mM.

### Claim 3 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the cell cycle blocking agent is selected from nocodazole, hydroxyurea; colchicine; demecolcine (colcemid); lovastatin; mimosine; thymidine; aphidicolin; latrunculin A; and latrunculin B.

### Claim 4 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the cell cycle blocking agent is thymidine.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein said culturing provides for production of the rAAV virions in an amount that is at least 1.5-fold higher than the amount produced when the eukaryotic cell is cultured in a control culture medium not comprising the cell cycle blocking agent in a concentration of from about 1 mM to about 100 mM.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the eukaryotic cell is a mammalian cell.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the eukaryotic cell is an insect cell.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the one or more heterologous gene products is a polypeptide.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the one or more heterologous gene products is a polynucleotide.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the one or more heterologous gene products comprise both a polypeptide and a polynucleotide.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the eukaryotic cell does not comprise a nucleic acid comprising nucleotide sequences encoding one or more adenoviral polypeptides.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, further comprising purifying the rAAV virions from the culture medium.

### Claim 13

A composition for the production of recombinant adeno-associated virus (rAAV) virions, the composition comprising:
a) eukaryotic cell comprising one or more nucleic acids comprising:
i) nucleotide sequences encoding AAV rep and cap gene products; and
ii) a nucleotide sequence encoding one or more heterologous gene products; and
b) a culture medium comprising a cell cycle blocking agent in a concentration of from about 1 mM to about 100 mM.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the culture medium comprises the cell cycle blocking agent in a concentration of from about 3 mM to about 10 mM.

### Claim 15 (depends on 13, 14)

The composition of claim 13 or claim 14, wherein the cell cycle blocking agent is selected from nocodazole, hydroxyurea; colchicine; demecolcine (colcemid); lovastatin; mimosine; thymidine; aphidicolin; latrunculin A; and latrunculin B.

### Claim 16 (depends on 13, 14)

The composition of claim 13 or claim 14, wherein the cell cycle blocking agent is thymidine.

### Claim 17 (depends on 13, 14, 15, 16)

The composition of any one of claims 13-16, wherein the one or more heterologous gene products is a polypeptide.

### Claim 18 (depends on 13, 14, 15, 16)

The composition of any one of claims 13-16, wherein the one or more heterologous gene products is a polynucleotide.

### Claim 19 (depends on 13, 14, 15, 16)

The composition of any one of claims 13-16, wherein the one or more heterologous gene products comprise both a polypeptide and a polynucleotide.

### Claim 20 (depends on 13, 14, 15, 16, 17, 18, 19)

The composition of any one of claims 13-19, wherein the eukaryotic cell does not comprise a nucleic acid comprising nucleotide sequences encoding one or more adenoviral polypeptides.

### Claim 21 (depends on 13, 14, 15, 16, 17, 18, 19, 20)

The composition of any one of claims 13-20, wherein the eukaryotic is a mammalian cell.

### Claim 22 (depends on 13, 14, 15, 16, 17, 18, 19, 20)

The composition of any one of claims 13-20, wherein the eukaryotic is an insect cell.
